Compare GoPro Inc (GPRO) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Nuvalent Inc — how do they compare? GoPro Inc trades at $0.67 (market cap $122.03M), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is far larger — about 80.4× GoPro Inc's market cap, and Nuvalent Inc is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| GPRO | NUVL | |
|---|---|---|
Market Cap | $122.03M | $9.81B |
Sector | Technology | Technology |
52-Week High | $2.88 | $123.96 |
52-Week Low | $0.64 | $72.16 |
Enterprise Value | $169.98M | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $0.6732, down 3.53% on the day, reflecting persistent financial stress with a net income margin of -20.7% and negative cash flow. The company is undergoing a strategic review for potential sale or merger, announced May 11, 2026, after receiving inbound interest. Technical indicators are bearish, with moving averages signaling continued downward pressure, while recent product launches like the MISSION 1 series aim to revive growth amid declining revenues.
The outlook hinges on the strategic review outcome; a successful sale could provide shareholder value, but ongoing losses and high burn rate pose significant risks. Investors face binary event-driven speculation, with analyst consensus mixed and substantial downside if restructuring fails.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, amid a pending $124 per share acquisition by GSK. The stock shows a bullish technical signal with moving averages supporting upside, though RSI levels suggest overbought conditions. Fundamentally, the company remains unprofitable with negative ROE and ROA, while cash flow is sustained by financing activities. Recent news is dominated by merger investigations and strategic rationale for the GSK deal.
The investment outlook hinges on the acquisition closing at $124, offering limited upside from current levels. Risks include shareholder litigation and regulatory scrutiny, but the deal provides a clear exit amid ongoing losses. Analyst sentiment is mixed with a slight hold bias, reflecting uncertainty around deal completion and fairness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
